The global biotech giant CSL Ltd (ASX: CSL) is experiencing a much-needed turnaround after a challenging two-year period. Once a pandemic-era success story, CSL faced a series of setbacks, including plasma collection disruptions, a costly acquisition, and rising costs, which impacted its earnings and investor sentiment. However, the company is now showing signs of recovery, and patient investors are finding the current situation particularly intriguing.
The Pandemic Hangover
The core issue for CSL in 2023 and 2024 was the lingering effects of the pandemic. Plasma collection centers struggled to regain donor volumes, leading to increased costs per litre of plasma. Simultaneously, the acquisition of Vifor Pharma for $16.4 billion added significant debt and integration challenges. These factors collectively weighed on CSL's performance.
Easing Headwinds
Fortunately, the winds are now changing. Plasma collection volumes have recovered significantly, and CSL's RIKA automated plasma collection technology is proving to be a game-changer, reducing costs and improving unit economics. The integration of Vifor's iron deficiency and nephrology products is also contributing positively to group earnings.
Positive Indicators
In the first half of FY2026, CSL reported impressive results, with net profit after tax reaching US$1.93 billion, a 16% increase year-over-year. The CSL Behring division demonstrated robust revenue growth of 13%. SEQIRUS, CSL's influenza vaccine business, continues to thrive due to growing demand for high-dose vaccines among older populations. Additionally, free cash flow is improving, and CSL has increased its interim dividend, indicating management's confidence in the company's earnings trajectory.
Long-Term Potential
CSL operates in markets with high barriers to entry, which is a significant advantage. Plasma-derived therapies require extensive manufacturing expertise, a large donor network, and regulatory approvals, making it difficult for new competitors to enter the market. The global demand for immunoglobulins, albumin, and clotting factors is expected to grow as populations age and access to specialist care improves in emerging markets.
Analysts' average price target for CSL shares is optimistic, suggesting that the current entry point offers a more attractive valuation compared to recent years. With a lower earnings multiple, investors can capitalize on CSL's long-term growth potential.
Foolish Takeaway
Despite the recent challenges, CSL shares present an enticing investment opportunity for long-term investors. The company's consistent earnings growth, expanding competitive advantage, and disciplined management team make it a strong contender in the large-cap space. While the past two years have been difficult, CSL's current position and future prospects are compelling, making it a wise choice for investors with a multi-year horizon.
